FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab  + cetuximab in pts w/ recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

For patients with R/M HNSCC, current treatments are palliative with anti-PD-1 checkpoint inhibitor +/- platinum and 5-fluorouracil chemotherapy for first-line followed by taxanes, methotrexate, and cetuximab as later-line options. The median overall survival (OS) for R/M patients is 10-13 months, and those with HPV-negative HNSCC face the worst outcomes.[1] Ficlatuzumab is a humanized IgG1 mAB against HGF, the ligand for the c-MET tyrosine kinase receptor. HGF/c-MET pathway dysregulation is frequently observed in HPV-negative HNSCC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: 148 Source Type: research